1,796 material Form 8-K filings that 1,448 companies we cover made with the SEC in May 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Bioventus disclosed that the FDA issued a final order on April 16, 2026 reclassifying non-invasive bone growth stimulators, including its Exogen Ultrasound Bone Healing System, from Class III to Class II devices. CMS also updated billing requirements and the Medicare fee schedule for these devices for dates of service on or after May 18, 2026, and the company reiterated its 2026 financial guidance, though it said further CMS changes could require a revised outlook.
FDA final order dated April 16, 2026 reclassified bone growth stimulators from Class III to Class II
CMS updated billing requirements and Medicare fee schedule under HCPCS codes E0747, E0748, and E0760 for dates of service on or after May 18, 2026
Bioventus does not presently expect reimbursement rate changes to have a material impact on 2026 results and reiterated its 2026 guidance
Future CMS changes to Exogen Medicare reimbursement rates could require a revised financial outlook
VenHub Global received a Nasdaq letter on May 21, 2026, confirming it has regained compliance with the $1.00 minimum closing bid price rule and that the matter is closed. The company's common stock closed at or above $1.00 for 10 consecutive business days from May 7 to May 20, 2026, removing a near-term risk of delisting from Nasdaq.
Nasdaq Listing Rule 5450(a)(1) compliance regained, per letter dated May 21, 2026
Compliance measured over 10 consecutive business days, May 7 to May 20, 2026, with closing bid at or above $1.00
Nasdaq has closed the matter; the filing does not describe any financial results or other terms
Hub Group received a Nasdaq notice that it is not in compliance with listing rules because it did not timely file its Form 10-Q for the quarter ended March 31, 2026, which follows its delayed 2025 Form 10-K. The notice has no immediate effect on the listing or trading of its Class A common stock, but the company is restating prior financial statements and must file its overdue reports by September 14, 2026 to avoid further listing action.
Nasdaq notice dated May 19, 2026 cites Listing Rule 5250(c)(1) for the late Q1 2026 Form 10-Q.
Nasdaq's exception period runs until September 14, 2026 for the company to regain compliance.
An updated compliance plan is due to Nasdaq by June 3, 2026.
Restatements cover 2024 and 2023 annual periods and the 2025 quarters ended March 31, June 30 and September 30.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.